Capital Point logo

Capital Point

Asia, Tel Aviv, Israel, Tel Aviv

Description

Capital Point is a Saudi Arabian investment firm offering venture capital to real estate and other projects.

Investor Profile

Capital Point has made 3 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series B (67%)
  • Seed (33%)

Country Focus

  • Israel (100%)

Industry Focus

  • Artificial Intelligence (Ai)
  • Human Computer Interaction
  • Robotics
  • Social
  • Software
  • Biotechnology
  • Pharmaceutical
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Capital Point frequently co-invest with?

iRobot
North America, Massachusetts, United States, Bedford
Co-Investments: 1
Toyota Ventures
North America, California, United States, Los Altos
Co-Investments: 1
Union Tech Ventures
Asia, Tel Aviv, Israel, Tel Aviv
Co-Investments: 1
Samsung NEXT
North America, California, United States, Mountain View
Co-Investments: 1
Happiness Capital
Asia, Hong Kong Island, Hong Kong, Hong Kong
Co-Investments: 1
OurCrowd
Asia, Yerushalayim, Israel, Jerusalem
Co-Investments: 1
Ibex Investors
North America, Colorado, United States, Denver
Co-Investments: 1
Bloomberg Beta
North America, California, United States, San Francisco
Co-Investments: 1
Sompo Holdings
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1
SPARX Group
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1

What are some of recent deals done by Capital Point?

Visionary.ai

Tel Aviv, Tel Aviv, Israel

Next-generation Image Signal Processing (ISP) that leverages the power of AI

Artificial Intelligence (AI)
SeedFeb 28, 2022
Amount Raised: $2,500,000
Intuition Robotics

Ramat Gan, Tel Aviv, Israel

Intuition Robotics provides care companion technologies for older adults.

Artificial Intelligence (AI)Human Computer InteractionRoboticsSocialSoftware
Series BFeb 13, 2020
Amount Raised: $36,000,000
RDD Pharma

Ofakim, HaDarom, Israel

Phase 3 and Phase 2 ongoing in lower gastrointestinal disorders

BiotechnologyPharmaceuticalTherapeutics
Series BNov 16, 2017
Amount Raised: $9,500,000